At its Annual General Meeting, Thyssenkrupp secured shareholder approval for a €0.15 per share dividend and detailed progress on its pivot to a holding structure, even as it navigates a costly 'year of implementation' with restructuring ahead.
The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.
Seaport Research has lowered its price target for Polaris Inc. (PII) following a strong fourth quarter overshadowed by softer-than-expected forward guidance. The firm maintains a Buy rating, citing the company's market share gains and operational improvements amidst ongoing tariff challenges.
President Trump's reported selection of former Fed Governor Kevin Warsh to lead the central bank signals a potential shift in monetary policy approach, with a focus on strategic foresight over data-dependency, according to economist Mohamed El-Erian.
After a November dip, Texas's upstream oil and gas sector added 2,000 jobs in December, contributing to the state's record-breaking employment figures and underscoring the industry's pivotal role in the Texan economy and tax base.
Taiwan Semiconductor Manufacturing Company (TSMC) announces a historic $165 billion investment to expand its advanced chipmaking facilities in Arizona, marking a significant deepening of U.S.-Taiwan economic and strategic ties.
As a temporary halt in Russian airstrikes on Kyiv brokered by former U.S. President Trump nears its end, Ukraine is urgently working to strengthen its air defenses. Analysts caution the lull may be a tactical move by Moscow to bolster its diplomatic leverage rather than a step toward peace.
With low adoption rates for brokerage 'trusted contacts,' regulators are considering a simple name change to 'emergency contact' to reduce confusion, ease client concerns, and strengthen protections against financial exploitation.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Cotton futures extended losses on Friday, pressured by a stronger U.S. dollar and a significant year-over-year decline in export commitments. The market's focus remains on demand concerns as key metrics lag behind historical averages.
While stocks priced between $10 and $50 often signal companies past their initial hurdles, some still grapple with unproven models and market volatility. We examine three such stocks where the risk may outweigh the potential reward.
While the consumer staples sector has lagged the broader market rally, select companies continue to demonstrate defensive strength and growth potential. We analyze one standout and two stocks facing significant headwinds.
While small-cap stocks can offer high-growth potential, their path is often fraught with operational challenges and valuation risks. We examine three companies where the risks may outweigh the rewards in the current market environment.
While the small-cap index is famed for its hidden gems, some constituents face headwinds that make them less compelling for growth-focused portfolios. Here's a look at three companies analysts are currently avoiding.
Cullen/Frost Bankers (NYSE: CFR) reported fourth-quarter revenue in line with expectations but delivered a significant earnings beat, driven by its aggressive branch network expansion in Texas and robust commercial lending. Management expressed confidence in sustained loan growth and improving margins for the coming year.
Xerox Holdings Corp. reported a 25.7% year-over-year revenue increase to $2.03 billion in Q4 2025, yet fell short of Wall Street expectations. The company's full-year guidance and per-share loss also disappointed analysts, as margin pressures and acquisition integration complexities weigh on its transformation journey.
Generating cash is just the first step. We analyze three companies to see which ones effectively convert that cash into lasting shareholder value and which ones struggle to capitalize on their financial strength.
While market darlings come and go, a select group of companies achieves sustained outperformance through a powerful trifecta: rising sales, expanding profitability, and efficient capital use. We examine three such names that have delivered triple-digit returns over the past five years.
Shares of semiconductor materials supplier Entegris have surged nearly 56% in six months, but analysts warn of stretched valuations, slowing growth forecasts, and weak cash generation, suggesting investors may want to look elsewhere for value.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
